Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CERo Therapeutics Holdings, Inc. - Common Stock (NQ: CERO )

1.095 +0.294 (+36.81%)
Streaming Delayed Price Updated: 2:08 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company’s Lead Compound CER-1236
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Highlights Progress
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics, Inc. Provides Corporate Update
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236
CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that 
Via PressReach
Exposures Product Safety
CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy
Disseminated on behalf of CERo Therapeutics Holdings. Cancer treatments have come a long way over the years, but there is a newer treatment that is providing even stage four cancer patients with a new... 
Via PressReach
CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics, Inc. Provides Corporate Update for Shareholders
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients
From CERo Therapeutics Holdings, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.